Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 1/20 | 0.43 |
| ▸ | BTK | Q06187 | 1/20 | 0.43 |
| ▸ | CTSS | P25774 | 2/20 | 0.43 |
| ▸ | CTSK | P43235 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | AAK1 | Q2M2I8 | 7/20 | 0.38 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.37 |
| ▸ | FAAH | O00519 | 1/20 | 0.36 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL33530612 | 1.00 | JAK3 (0.43) | JAK3BTKCTSSCTSKMEN1 | |
| SCHEMBL15670019 | 0.87 | JAK3 (0.43) | JAK3BTKCTSSCTSKMEN1 | |
| SCHEMBL14847753 | 0.87 | S1PR3 (0.45) | JAK3BTKCTSSCTSKRAB9A | |
| SCHEMBL2834038 | 0.87 | S1PR3 (0.45) | JAK3BTKCTSSCTSKRAB9A | |
| SCHEMBL14847752 | 0.87 | S1PR3 (0.45) | JAK3BTKCTSSCTSKRAB9A | |
| SCHEMBL16847362 | 0.87 | CTSK (0.56) | JAK3BTKCTSSCTSKMAPT | |
| SCHEMBL90836 | 0.87 | CTSK (0.56) | JAK3BTKCTSSCTSKMAPT | |
| SCHEMBL2837436 | 0.85 | JAK3 (0.42) | JAK3BTKCTSSCTSKMAPT | |
| SCHEMBL3503830 | 0.82 | CTSS (0.47) | CTSSCTSKMEN1KMT2ANPC1 | |
| SCHEMBL26648713 | 0.82 | MEN1 (0.48) | MEN1KMT2ATDP1SMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260092057-A1 | BCL-XL/BCL-2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-04-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260092057-A1 | BCL-XL/BCL-2 DEGRADERS AND USES THEREOF | BCL2L2, BCL2A1, BCL2L1 | JAK3 3054/4885BTK 1337/4885CTSS 2097/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.